MARKET

REVBU

REVBU

Revelation Biosciences Inc
NASDAQ
0.3200
-0.0010
-0.31%
Closed 16:00 09/30 EDT
OPEN
0.3500
PREV CLOSE
0.3210
HIGH
0.3500
LOW
0.3000
VOLUME
4.10K
TURNOVER
135
52 WEEK HIGH
22.50
52 WEEK LOW
0.3000
MARKET CAP
2.33M
P/E (TTM)
-0.1911
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Ontrak (NASDAQ:OTRKP) shares increased by 28.8% to $2.1 during Monday's pre-market session.
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 08/30 12:18
BRIEF-Revelation Biosciences Announces Results For Quarter Ended June 30
BRIEF-Revelation Biosciences Announces Results For Quarter Ended June 30
Reuters · 08/15 21:34
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatme...
GlobeNewswire · 08/15 21:30
BRIEF-Revelation Biosciences Inc Announces Pricing Of $5 Million Public Offering
BRIEF-Revelation Biosciences Inc Announces Pricing Of $5 Million Public Offering
Reuters · 07/26 12:18
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatme...
GlobeNewswire · 07/26 12:15
11 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 07/25 12:16
BRIEF-Revelation Biosciences Announces Topline Data For Phase 1B Clear Clinical Study Of Revtx-99B For Treatment Of Allergic Rhinitis
BRIEF-Revelation Biosciences Announces Topline Data For Phase 1B Clear Clinical Study Of Revtx-99B For Treatment Of Allergic Rhinitis
Reuters · 07/22 22:31
More
About REVBU
Revelation Biosciences, Inc., formerly Petra Acquisition, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development or commercialization of innate immune system therapeutics and diagnostics. Its clinical and nonclinical stage therapeutic and diagnostic platforms is applied to a range of viral infections, including SARS-CoV-2, variants of SARS-CoV-2, Influenza A, Influenza B, parainfluenza, respiratory syncytial virus, rhinosinusitis, and others. Its lead therapeutic product candidate includes REVTx-99, REVTx-200 and REVDx-501. REVTx-99 is developed as an anti-viral nasal drop for the prevention or treatment of respiratory viral infections, including nasal congestion due to allergies or chronic rhinosinusitis. REVTx-200 is developed as an intranasal therapy that is administered with intramuscular (IM) vaccine. REVDx-501 (REVID Rapid Test Kit) is a lead diagnostic device program, which is developed to detect various respiratory viral infection.

Webull offers kinds of Revelation Biosciences Inc stock information, including NASDAQ:REVBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REVBU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REVBU stock methods without spending real money on the virtual paper trading platform.